You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《异动股》先声药业(02096.HK)续涨逾12%价量齐创近七个月高
阿思达克 05-27 14:42
先声药业(02096.HK)三连升,继昨天以逾半年大成交股价急涨10%突破野村上月首予目标价10.1元後,今早曾进一步升破瑞银上月首予目标价10.8元,最高见10.88元,创近七个月高,现造10.5元,续涨逾12%,成交进一步增至1,445万股,同创近七个月高,涉资逾1.5亿元。

先声是内地生物化学制药集团,目前主要从事仿制药业务。公司於以下专注战略性治疗领域拥有多元化的产品组合,分别有肿瘤、中枢神经系统及自身免疫疾病。股份於去年10月27日以每股13.7元来港上市。挂牌後股价一直「潜水」,最高仅於上市第四天高见11.68元已行人止步,去年11月27日曾跌至7.65元喘定回升。

瑞银上月下旬指出,先声正由药品公司转型至研发主导公司,当中以中央肿瘤科神经系统(CNS)和自身免疫性疾病为主,并相信公司具备丰富的药物组合,料未来四年收入与纯利年复合增长率分别为19%及21%,故首予其「买入」评级及目标价10.8元。此外,野村上月中也料先声治疗中枢神经系统疾病及自体免疫性疾病的药物销售增长,将带动公司未来三年收入及盈利年复合率增长分别为20%及22%,故首予先声药业「买入」评级及目标价10.1元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account